ClinicaliQ Trial Snapshot
- Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T) — Active Not Recruiting • Phase III • Oncology • NCT05629234.
- Osimertinib continuation study for cancer patients benefiting from treatment in previous trials.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The rationale of the ROSY-T study is to continue to provide study treatment for patients who have participated in a parent study with osimertinib and who are continuing to derive clinical benefit from treatment at the end of such studies, as judged by the Investigator. Conditions: Cancer Interventions: Osimertinib Lead Sponsor: AstraZeneca Planned Enrollment: 37 participants